Investigator-Sponsored Protocol - Continued Use of Ibalizumab

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01056393
Recruitment Status : Completed
First Posted : January 26, 2010
Last Update Posted : July 12, 2018
TaiMed Biologics Inc.
Information provided by (Responsible Party):
William J. Towner, Kaiser Permanente

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : December 15, 2016
  Actual Study Completion Date : December 15, 2016
  Certification/Extension First Submitted : April 11, 2018